Pharmaceuticals IT & AI consultingFew industries pay more for getting tech wrong.
A data integrity finding can idle a production line, a validation gap can stall a submission, and an unmanaged AI tool can draw a warning letter on its own.
Primary shape of the AI dividend this year: Rollup.
Pressure from both directions.
Boards want AI accelerating discovery and operations, while regulators expect control and evidence behind every system.
We place fractional CIO leadership inside pharmaceutical organizations through Contract CIO+®, provide standing counsel through CIO IQ®, and guide AI in regulated settings.
Pharma in 2026.
Acceleration on every front at once.
Data integrity
A data integrity finding can idle a production line.
Submissions
A validation gap can stall a submission.
Warning-letter risk
An unmanaged AI tool can draw a warning letter all by itself.
Fast science and regulators
The science, the regulators, and the trade environment are all moving fast.
Rollup
Primary shape of the AI dividend this year.
Our top-line approach.
Speed and control, together.
Stabilize
Secure and validate the systems regulators inspect.
Optimize
Streamline data and operations without losing evidence.
Monetize
Use governed AI to accelerate science and operations.
Talk with a pharmaceutical technology leader.
A former CIO, CTO, or CISO from the sector, vendor-neutral, with the only agenda yours.